ReviewPsoriasis (Auckland, N.Z.)2023
The Skin Microbiome and Its Role in Psoriasis: A Review.
Review in Psoriasis (Auckland, N.Z.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07169019 (Gut Microbiome Changes and Clinical Impact Induced by Treatment of Newly Diagnosed Psoriasis Patients With Probiotics and Methotrexate), which is not on this map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Gut Microbiome Changes and Clinical Impact Induced by Treatment of Newly Diagnosed Psoriasis Patients With Probiotics and Methotrexate: a Pilot Study
Who cites it
22 citing papers in PubMed, 52 citations in OpenAlex.
- The Immunological Intersection of Psoriasis and Autoimmune Diseases: Shared Pathways and Clinical Implications.Life (Basel, Switzerland) · 2026Review
- Skin Microbiome in Health and Disease: Dysbiosis and the Emerging Role of Biotics in Therapy and Protection.International journal of molecular sciences · 2026Review
- Transferosomes Containing 20-Hydroxyecdysone for Psoriasis Treatment: Preparation, Characterization, and In Vitro and In Vivo Toxicity Assessment.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Pharmacomicrobiomics in Psoriasis: Microbiome-Drug Interactions Across Systemic Treatments.Life (Basel, Switzerland) · 2026Review
- Psoriasis: microbiome dysbiosis and pathogenic mechanisms.Frontiers in immunology · 2026Review
- Cutaneous Adverse Events of Tyrosine Kinase Inhibitors in Endocrine Tumors: Clinical Features, Mechanisms, and Management Strategies.Biomedicines · 2025Review
- The Skin Microbiome and Bioactive Compounds: Mechanisms of Modulation, Dysbiosis, and Dermatological Implications.Molecules (Basel, Switzerland) · 2025Review
- Association of skin microbiome with interleukin-23 in patients with plaque psoriasis.Postepy dermatologii i alergologii · 2025Article
- Alternatives Integrating Omics Approaches for the Advancement of Human Skin Models: A Focus on Metagenomics, Metatranscriptomics, and Metaproteomics.Microorganisms · 2025Review
- The Role of Microbiota in the Pathogenesis of Bullous Pemphigoid and Pemphigus Vulgaris: Evidence, Controversies, and Perspectives.International journal of molecular sciences · 2025Review
- Exposure to green space is associated with higher skin microbiota species richness in children.PNAS nexus · 2025Article
- Microbial imbalance in Darier disease: Dominance of various staphylococcal species and absence of Cutibacteria.Scientific reports · 2024Article
- The Contribution of the Skin Microbiome to Psoriasis Pathogenesis and Its Implications for Therapeutic Strategies.Medicina (Kaunas, Lithuania) · 2024Review
- Shared Pathophysiology of Inflammatory Bowel Disease and Psoriasis: Unraveling the Connection.Cureus · 2024Review
- Microbiome-Mucosal Immunity Nexus: Driving Forces in Respiratory Disease Progression.Journal of microbiology (Seoul, Korea) · 2024Review
- Review
- An Eastern County from an European Eastern Country-The Characteristics of Cutaneous Microbiome in Psoriasis Patients-Preliminary Results.Life (Basel, Switzerland) · 2024Article
- Does "all disease begin in the gut"? The gut-organ cross talk in the microbiome.Applied microbiology and biotechnology · 2024Review
- Review: A Contemporary, Multifaced Insight into Psoriasis Pathogenesis.Journal of personalized medicine · 2024Review
- Microbiome Dynamics: A Paradigm Shift in Combatting Infectious Diseases.Journal of personalized medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The skin microbiome is made of various microorganisms, most of which have the function of protecting individuals from harmful pathogens, and they are involved in innate and adaptive immune responses. The skin acts as a physical and immunological barrier against external stimuli, including pathogens and physical damage. Changes in the composition of the skin microbiome can trigger inflammatory processes leading to inflammatory skin diseases in susceptible individuals. Psoriasis (PsO) is a chronic inflammatory disease with a multifactorial etiology, where breakdown of immune tolerance to cutaneous microorganisms is implicated in its pathogenesis. Dysregulation of the microbiome due to genetic and environmental factors plays a significant role in the development of psoriatic disease. Dermatologic conditions such as atopic dermatitis, acne, psoriasis, and rosacea have been associated with intestinal dysbiosis. The skin microbiota composition is crucial for the development of appropriate immune responses, and alterations in the skin microbiome can contribute to changes in physiology and susceptibility to skin diseases or inflammatory conditions. Understanding the microbial settlement of the skin and the network of interactions that occur throughout life is essential for comprehending the pathogenesis of skin diseases and developing innovative treatments. With this article we tried to explore the relationship between the human microbiome and psoriatic disease, shedding light on the functions of the microbiome and the inflammatory disease processes to identify additional therapeutic targets. This review aims to highlight the relationship between skin and gut microbiome functions and inflammatory processes in skin psoriasis and psoriatic arthritis (PsA). The goal is to facilitate future studies on the skin microbiome to identify potential novel therapies for patients with psoriatic disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.